Health Care·Pharmaceuticals·$789.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.10 | N/A | +195.24% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.10 | N/A | +195.24% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering innovative treatments.
Eli Lilly's strong EPS performance, significantly exceeding expectations, led to a positive stock reaction, with shares rising by 4.66%. The company did not disclose revenue figures or future guidance, leaving some uncertainty. Investors may view the EPS beat as a sign of strong operational performance, but the lack of revenue data could raise questions about overall growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MCDONALDS CORP
Oct 30, 2023